ADMA Lawsuit Alleges Channel Stuffing, Undisclosed Related Party; Lead Plaintiff Deadline Set
ADMA sits 23% above its 52-week low of $7.21 on light trading volume (0.1× avg).
Summary
A securities class action against ADMA Biologics now has a court-set lead plaintiff deadline of August 10, 2026. The complaint alleges the company inflated ASCENIV revenue through channel stuffing and failed to disclose sales to a related party, Genesis BioPharma Services, which operated from ADMA's headquarters. The CFO departed abruptly in February 2026 with only one week's notice. These new details go beyond the earlier lawsuit announcements, adding specifics about the alleged scheme and internal control failures. The stock remains under pressure from the March 2026 short report that initially raised these issues.
At the time of this announcement, ADMA was trading at $8.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $7.21 to $20.46. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.